JCB, Volume 14, Number 1, 2008 Editorial Vol.14 No. 1 (2008) Editorial Yali Friedman   Article Vol.14 No. 1 (2008) The ability to pick biotech talent: Being a better interviewer moves ‘you’ up the ladder David G Jensen Do you know someone who has this unique skill? That person generally is respected throughout the company for his or her ability to interview well, and to spot those few who Article Vol.14 No. 1 (2008) How the UN's anti-biotech policies worsen global warming Henry I Miller Numerous United Nations policies and programmes inhibit the development and use of important tools that could help both to reduce carbon dioxide emissions and to conser Article Vol.14 No. 1 (2008) Building a conducive environment for life science-based entrepreneurship and industry clusters Mark J Ahn The global biopharmaceutical industry, with over $70bn in revenues and 700 publicly listed firms posting double-digit growth in North America, E Article Vol.14 No. 1 (2008) Cloning an industry: Strategy typologies of Shanghai biotechnology companies Ken Malone Insight into the development of the medicinal biotechnology sector of China is provided through interviews of 19 Shanghai-based companies. Two commonly accepted strateg Article Vol.14 No. 1 (2008) Biotechnology in India: Public–private partnerships Viren Konde As the purpose of this study was a survey of public sector–private industry collaborations of the biotechnology sector in India, an organisational and functional Article Vol.14 No. 1 (2008) Biogenerics 2007: How far have we come? John Tucker The recent approval of a follow-on version of Pfizer's Genotropin (recombinant human growth hormone) signalled the beginning of the end of an era in which biopharmaceut Article Vol.14 No. 1 (2008) Monoclonal antibody therapeutics: Leading companies to maximise sales and market share Karl Ziegelbauer A close look at the biology and pharmacology of monoclonal antibodies reveals both their continuing promise as therapeutic agents to address unmet medical needs, as wel Article Vol.14 No. 1 (2008) Globalising clinical development in Japan Yorozu Tabata Most global pharmaceutical companies, no matter where they are headquartered, are struggling to effectively integrate their Japanese operations into a new global struct From the Classroom Vol.14 No. 1 (2008) Bioentrepreneurship education programmes in the United States Arlen D Meyers In this first paper of a new regular column, Arlen Meyers and Patrick Hurley review the different bioentrepreneurship education programmes available in the United State Legal and Regulatory Updates Vol.14 No. 1 (2008) Legal and regulatory update John Wilkinson  Â
